These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33613729)

  • 21. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
    Liu F; Bayliss G; Zhuang S
    Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases.
    Rockel JS; Rabani R; Viswanathan S
    Semin Cell Dev Biol; 2020 May; 101():87-103. PubMed ID: 31757583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect and mechanism of fluorofenidone on organ fibrosis].
    Ma H; Peng Z; Hu G; Tao L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Feb; 40(2):208-13. PubMed ID: 25769329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to prevent and reverse liver fibrosis in humans and laboratory animals.
    Chen RJ; Wu HH; Wang YJ
    Arch Toxicol; 2015 Oct; 89(10):1727-50. PubMed ID: 25963329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacological approach to reverse portal hypertention and hepatic schistosomal fibrosis in Egypt, control experimental study.
    Helmy AH; Abdel-Hady AA; el-Shanawany F; Hammam O; Abdel-Hady A
    J Egypt Soc Parasitol; 2005 Dec; 35(3):731-50. PubMed ID: 16333884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
    Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
    Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunomodulatory role of interleukin-35 in fibrotic diseases.
    Luo M; Peng H; Chen P; Zhou Y
    Expert Rev Clin Immunol; 2019 Apr; 15(4):431-439. PubMed ID: 30590954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Vascular Involvement in Soft Tissue Fibrosis-Lessons Learned from Pathological Scarring.
    Huang C; Ogawa R
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32268503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomaterials, fibrosis, and the use of drug delivery systems in future antifibrotic strategies.
    Love RJ; Jones KS
    Crit Rev Biomed Eng; 2009; 37(3):259-81. PubMed ID: 20402622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-induced drug targeting using novel peptide-ligand albumins.
    Meijer DK; Beljaars L; Molema G; Poelstra K
    J Control Release; 2001 May; 72(1-3):157-64. PubMed ID: 11389994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney.
    Teekamp N; Van Dijk F; Broesder A; Evers M; Zuidema J; Steendam R; Post E; Hillebrands JL; Frijlink HW; Poelstra K; Beljaars L; Olinga P; Hinrichs WLJ
    Int J Pharm; 2017 Dec; 534(1-2):229-236. PubMed ID: 29038068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The progress of topical drug delivery to the inner ear for the inhibition of inflammation and fibrosis following cochlear implantation].
    Yu HR; Jia H; Yang J
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):69-72. PubMed ID: 30704176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?
    Song K; Li Q; Yin XY; Lu Y; Liu CF; Hu LF
    Oxid Med Cell Longev; 2015; 2015():458720. PubMed ID: 26078807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonin: the dawning of a treatment for fibrosis?
    Hu W; Ma Z; Jiang S; Fan C; Deng C; Yan X; Di S; Lv J; Reiter RJ; Yang Y
    J Pineal Res; 2016 Mar; 60(2):121-31. PubMed ID: 26680689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
    Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
    Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recent Progress of Therapeutic Strategy and Laboratory Examination Against Chronic Liver Diseases].
    Yoshiji H
    Rinsho Byori; 2016 Sep; 64(9):1065-1071. PubMed ID: 30609460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery.
    Yhee JY; Im J; Nho RS
    J Clin Med; 2016 Sep; 5(9):. PubMed ID: 27657144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
    Fang L; Murphy AJ; Dart AM
    Front Pharmacol; 2017; 8():186. PubMed ID: 28428753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.
    Jaroszewicz J; Flisiak-Jackiewicz M; Lebensztejn D; Flisiak R
    Expert Opin Investig Drugs; 2015; 24(9):1229-39. PubMed ID: 26122697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.
    Czaja AJ
    Aliment Pharmacol Ther; 2014 Feb; 39(4):385-406. PubMed ID: 24387318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.